Pridopidine’s Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) is the first submission for approval for an investigational new treatment for adults with Huntington’s ...

Mid-cap stocks are presenting a golden opportunity for investors, offering a compelling combination of stability and ...

Dyskinetic Cerebral Palsy (CP) is a type of cerebral palsy that affects movement control. Individuals with this condition ...

NBI-1117568 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Schizophrenia.

To address the unmet need for a cure for RTT, the therapeutic potential of adult Neural Precursor Cells (NPCs) was ...